文献速递神经肿瘤

多中心研究对成人H3 K27M突变胶质瘤的见解:手术切除对总生存影响有限,ATRX作为分子预后标志物

Insights from a multicenter study on adult H3 K27M-mutated glioma: Surgical resection's limited influence on overall survival, ATRX as molecular prognosticator.
PubMed 文献 · Neuro Oncol · 2024-01-01

该多中心研究纳入2016至2022年诊断的70例≥18岁分子确诊H3 K27M突变胶质瘤患者,中位总生存13.6±14个月。全切除占14.3%、次全切除占30%、活检占54.3%。切除相比活检无生存获益(12 vs 11个月,P=.4006)。ATRX缺失独立关联总生存延长(31 vs 8.3个月,P=.0029)。

要点

  • 成人H3 K27M突变胶质瘤中位总生存13.6±14个月,切除与活检生存无差异(12 vs 11个月,P=.4006)。
  • ATRX缺失见于25.7%患者,独立关联总生存延长(31 vs 8.3个月,P=.0029)。
  • 中脑/后脑定位总生存较长(25.0 vs 8.7个月,P=.007),术前KPS≤80总生存较短(4.2 vs 18个月,P=.02)。

核心结论

  • 成人H3 K27M突变胶质瘤中,ATRX状态、肿瘤位置和KPS显著影响总生存,切除相比活检不提供生存优势。

研究设计与样本

  • 多中心研究,纳入2016至2022年诊断的70例≥18岁分子确诊H3 K27M突变胶质瘤患者,分析临床、影像和手术特征,行单变量和多变量分析。

主要发现

  • 70例患者平均年龄36.1岁,中位总生存13.6±14个月。
  • 全切除占14.3%,次全切除占30%,活检占54.3%。
  • 端脑/间脑/末脑定位总生存较差,中脑/后脑定位总生存显著较长(25.0 vs 8.7个月,P=.007)。
  • 术前KPS≤80总生存缩短(4.2 vs 18个月,P=.02)。
  • ATRX缺失见于25.7%患者,独立关联总生存延长(31 vs 8.3个月,P=.0029)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: H3 K27M-mutated gliomas were first described as a new grade 4 entity in the 2016 World Health Organization classification. Current studies have focused on its typical appearance in children and young adults, increasing the need to better understand the prognostic factors and impact of surgery on adults. Here, we report a multicentric study of this entity in adults. METHODS: We included molecularly confirmed H3 K27M-mutated glioma cases in patients ≥ 18 years diagnosed between 2016 and 2022. Clinical, radiological, and surgical features were analyzed. Univariate and multivariate analyses were performed to identify prognostic factors. RESULTS: Among 70 patients with a mean age of 36.1 years, the median overall survival (OS) was 13.6 ± 14 months. Gross-total resection was achieved in 14.3% of patients, whereas 30% had a subtotal resection and 54.3% a biopsy. Tumors located in telencephalon/diencephalon/myelencephalon were associated with a poorer OS, while a location in the mesencephalon/metencephalon showed a significantly longer OS (8.7 vs. 25.0 months, P = .007). Preoperative Karnofsky-Performance Score (KPS) ≤ 80 showed a reduced OS (4.2 vs. 18 months, P = .02). Furthermore, ATRX loss, found in 25.7%, was independently associated with an increased OS (31 vs. 8.3 months, P = .0029). Notably, patients undergoing resection showed no survival benefit over biopsy (12 vs. 11 months, P = .4006). CONCLUSIONS: The present study describes surgical features of H3 K27M-mutated glioma in adulthood in a large multicentric study. Our data reveal that ATRX status, location and KPS significantly impact OS in H3 K27M-mutated glioma. Importantly, our dataset indicates that resection does not offer a survival advantage over biopsy.

来源:Neuro Oncol,查看原文。版权归原作者所有。

引用

  1. Ryba A, Özdemir Z, Nissimov N, et al. Insights from a multicenter study on adult H3 K27M-mutated glioma: Surgical resection's limited influence on overall survival, ATRX as molecular prognosticator. Neuro Oncol. 2024. PMID: 38507506. doi:10.1093/neuonc/noae061

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。